MCID: GNR004
MIFTS: 53

Generalized Anxiety Disorder

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Generalized Anxiety Disorder

MalaCards integrated aliases for Generalized Anxiety Disorder:

Name: Generalized Anxiety Disorder 12 76 37 55 15 63 73
Anxiety Generalized 55

Classifications:



External Ids:

Disease Ontology 12 DOID:14320
ICD10 33 F41.1
ICD9CM 35 300.02
NCIt 50 C92622
SNOMED-CT 68 21897009
KEGG 37 H01662
UMLS 73 C0270549

Summaries for Generalized Anxiety Disorder

PubMed Health : 63 About generalized anxiety disorder: Everyone feels frightened or very scared every once in a while. In dangerous situations, for instance on the highway, fear can help to protect you. It puts the body in a state of readiness so that it can react to threats quickly. Worries and anxiety about the future, your job or family might also help to guard against danger. For example, by keeping you from making rash decisions that could lead to difficult situations.But if these sorts of fears become overwhelming, they can be very distressing. Some people end up constantly worrying about practically everything. If fears and anxiety overshadow everything else and don’t go away, the person may have developed generalized anxiety disorder (GAD). People with generalized anxiety disorder usually realize that their fears are exaggerated, but they aren’t able to control them. Although it’s difficult to get out of this state, there are treatments that can help.

MalaCards based summary : Generalized Anxiety Disorder, also known as anxiety generalized, is related to anxiety and depression. An important gene associated with Generalized Anxiety Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Circadian rythm related genes and cAMP signaling pathway. The drugs Alprazolam and Valproic Acid have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An anxiety disorder that is characterized by long-lasting anxiety that is not focused on any one object or situation.

Wikipedia : 76 Generalized anxiety disorder (GAD) is an anxiety disorder characterized by excessive, uncontrollable and... more...

Related Diseases for Generalized Anxiety Disorder

Diseases related to Generalized Anxiety Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
# Related Disease Score Top Affiliating Genes
1 anxiety 31.2 BDNF COMT CRHR1 HTR1A HTR2A HTR3A
2 depression 30.5 BDNF CRHR1 HTR1A HTR2A MAOA SLC6A4
3 agoraphobia 30.5 HTR1A MAOA SLC6A2 SLC6A4
4 dysthymic disorder 30.3 HTR2A MAOA SLC6A4
5 social phobia 30.2 DRD2 HTR1A HTR3A MAOA SLC6A4
6 irritable bowel syndrome 29.8 CRHR1 HTR3A SLC6A4 TPH1
7 anorexia nervosa 29.8 BDNF COMT HTR2A SLC6A4
8 phobia, specific 29.8 COMT MAOA
9 alexithymia 29.6 COMT DRD2 HTR1A SLC6A4
10 neuroleptic malignant syndrome 29.5 DRD2 HTR1A
11 antisocial personality disorder 29.5 COMT DRD2 MAOA SLC6A4
12 chronic fatigue syndrome 29.4 COMT HTR1A HTR2A MAOA SLC6A4
13 obsessive-compulsive disorder 29.4 BDNF COMT DRD2 HTR1A HTR2A HTR3A
14 substance dependence 29.3 BDNF DRD2 MAOA SLC6A4
15 substance abuse 29.3 BDNF COMT DRD2 MAOA SLC6A4
16 bruxism 29.3 DRD2 HTR2A
17 eating disorder 29.3 BDNF COMT DRD2 SLC6A4
18 post-traumatic stress disorder 29.2 BDNF COMT DRD2 HTR2A MAOA SLC6A4
19 personality disorder 29.1 BDNF COMT DRD2 HTR1A HTR2A MAOA
20 oppositional defiant disorder 29.1 COMT DRD2 MAOA SLC6A2 SLC6A4
21 panic disorder 29.1 BDNF COMT CRHR1 HTR1A HTR2A HTR3A
22 borderline personality disorder 29.0 BDNF COMT HTR1A HTR2A MAOA SLC6A4
23 attention deficit-hyperactivity disorder 29.0 BDNF COMT DRD2 HTR1A HTR2A MAOA
24 major depressive disorder 28.9 BDNF COMT CRHR1 DRD2 HTR1A HTR2A
25 bipolar disorder 28.8 BDNF COMT DRD2 HTR1A HTR2A HTR3A
26 mood disorder 28.5 BDNF COMT CRHR1 DRD2 HTR1A HTR2A
27 schizophrenia 28.4 BDNF COMT DRD2 HTR1A HTR2A HTR3A
28 mental depression 28.3 BDNF COMT CRHR1 HTR1A HTR2A MAOA
29 alcohol dependence 27.8 BDNF COMT CRHR1 DRD2 HTR1A HTR2A
30 sexual disorder 10.2 HTR1A SLC6A4
31 schizoid personality disorder 10.2 HTR1A HTR2A
32 hypoactive sexual desire disorder 10.2 HTR1A HTR2A
33 psychosexual disorder 10.2 HTR1A HTR2A SLC6A4
34 atypical depressive disorder 10.1 HTR2A MAOA SLC6A4
35 rumination disorder 10.1 HTR1A HTR3A
36 intermittent explosive disorder 10.1 HTR1A SLC6A4
37 kleptomania 10.1 HTR1A MAOA SLC6A4
38 schizophrenia 5 10.1 COMT HTR2A
39 motion sickness 10.1 HTR1A HTR3A
40 tic disorder 10.1 DRD2 HTR2A
41 temporal lobe epilepsy 10.1 BDNF HTR1A TSPO
42 dyspepsia 10.1 HTR1A HTR3A SLC6A4
43 avoidant personality disorder 10.1 MAOA SLC6A4 TPH1
44 autism spectrum disorder 10.1 BDNF HTR2A SLC6A4
45 central nervous system disease 10.0 BDNF HTR2A SLC6A2 SLC6A4
46 alcohol-induced mental disorder 10.0 DRD2 SLC6A4
47 coronary heart disease 1 10.0
48 heart disease 10.0
49 epilepsy 10.0
50 amnestic disorder 10.0 BDNF HTR1A HTR3A TSPO

Comorbidity relations with Generalized Anxiety Disorder via Phenotypic Disease Network (PDN): (show all 19)


Acute Cystitis Anxiety
Bronchitis Chronic Myocardial Ischemia
Dependent Personality Disorder Dysthymic Disorder
Esophagitis Histrionic Personality Disorder
Hypertension, Essential Hypochondriasis
Hypothyroidism Irritable Bowel Syndrome
Major Depressive Disorder Obsessive-Compulsive Disorder
Obsessive-Compulsive Personality Disorder Osteoporosis
Personality Disorder Schizophreniform Disorder
Somatization Disorder

Graphical network of the top 20 diseases related to Generalized Anxiety Disorder:



Diseases related to Generalized Anxiety Disorder

Symptoms & Phenotypes for Generalized Anxiety Disorder

GenomeRNAi Phenotypes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Generalized Anxiety Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 BDNF COMT CRHR1 DRD2 HTR1A HTR2A
2 cardiovascular system MP:0005385 10.02 COMT CRHR1 DRD2 HTR1A MAOA RGS2
3 homeostasis/metabolism MP:0005376 9.9 BDNF COMT CRHR1 DRD2 HTR1A HTR3A
4 endocrine/exocrine gland MP:0005379 9.86 BDNF COMT CRHR1 DRD2 HTR2A HTR3A
5 muscle MP:0005369 9.43 DRD2 HTR2A HTR3A RGS2 SLC6A4 TPH1
6 nervous system MP:0003631 9.32 BDNF COMT CRHR1 DRD2 HTR1A HTR3A

Drugs & Therapeutics for Generalized Anxiety Disorder

PubMedHealth treatment related to Generalized Anxiety Disorder: 63

There are different ways to gradually get a handle on an anxiety disorder. It is unrealistic to expect a quick and simple “cure,” but you can find better ways to deal with stress and anxiety. Medication may also relieve some of the symptoms. There are different kinds of treatment approaches:Psychological treatments: These include approaches like cognitive behavioral therapy. This therapy can help you to learn how to control and then change your thoughts and fears.Relaxation techniques such as autogenic training and progressive muscle relaxation can help you to relax and handle stress better. These techniques are often part of psychological treatment.Medication: The most commonly used medications for anxiety disorders are antidepressants. Some people also use herbal sedatives such as valerian.Self-help: Self-help groups offer you the opportunity to share your thoughts, feelings and experiences with others who have the same condition. Some people also find it helpful to learn more about the disorder – be it from books, information leaflets or on the Internet.It is hard to get a handle on severe anxiety, but many people succeed over time. A therapist can help to reveal the underlying patterns of the worries and anxiety. With their guidance, it is possible to learn how to control harmful thoughts and behavior patterns so that they no longer dominate your life. It can take a lot of patience to find your way back to a life with less anxiety, but a noticeable improvement can often already be achieved after a few weeks.

Drugs for Generalized Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 474)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alprazolam Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 28981-97-7 2118
2
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
3
Interferon beta-1b Approved Phase 4,Phase 2,Phase 3 145155-23-3
4
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
5
Racepinephrine Approved Phase 4,Not Applicable 329-65-7 838
6
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
7
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
8
Sertraline Approved Phase 4,Phase 2,Phase 3,Not Applicable 79617-96-2 68617
9
Citalopram Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
11
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
12
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61869-08-7 43815
13
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
14
Nicotine Approved Phase 4,Phase 2,Phase 3,Not Applicable 54-11-5 942 89594
15
Tramadol Approved, Investigational Phase 4,Phase 2,Not Applicable 27203-92-5 33741
16
Ketamine Approved, Vet_approved Phase 4,Not Applicable 6740-88-1 3821
17
Buspirone Approved, Investigational Phase 4,Phase 2,Not Applicable 36505-84-7 2477
18
Lorazepam Approved Phase 4,Phase 3,Phase 2,Not Applicable 846-49-1 3958
19
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3 148553-50-8 5486971
20
Eszopiclone Approved, Investigational Phase 4,Phase 3,Phase 2 138729-47-2 969472
21
Ziprasidone Approved Phase 4 146939-27-7 60854
22
Chamomile Approved, Experimental, Investigational Phase 4,Phase 3
23
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
24
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
25
Tiagabine Approved, Investigational Phase 4,Phase 3 115103-54-3 60648
26
Zolpidem Approved Phase 4,Not Applicable 82626-48-0 5732
27
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
28
Varenicline Approved, Investigational Phase 4,Phase 2 249296-44-4 5310966
29
Meperidine Approved Phase 4 57-42-1 4058
30
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
31
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
32
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
33
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
34
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 56-12-2 119
35
Ivacaftor Approved Phase 4 873054-44-5 16220172
36
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 175805 71273
37
Tamoxifen Approved Phase 4,Phase 2 10540-29-1 2733526
38
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
39
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
40
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
41
Chlordiazepoxide Approved, Illicit, Investigational Phase 4 58-25-3 2712
42
Lithium carbonate Approved Phase 4 554-13-2
43
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
44
Methadone Approved Phase 4 76-99-3 4095
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
46 Kava Approved, Investigational, Nutraceutical Phase 4,Phase 2 9000-38-8
47 Tandospirone Investigational Phase 4 87760-53-0
48 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1210)
# Name Status NCT ID Phase Drugs
1 Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder Unknown status NCT01614041 Phase 4 Usual dose treatment of Tandospirone;Comparative high dose of tandospirone treatment
2 Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder Unknown status NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
3 Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD Unknown status NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
4 Mindfulness-Based Cognitive Therapy for Depression and Anxiety Unknown status NCT02777905 Phase 4
5 Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI Unknown status NCT00176592 Phase 4 Betaseron;Copaxone
6 Sodium Bicarbonate in Cardiopulmonary Resuscitation Unknown status NCT01377337 Phase 4 sodium bicarbonate
7 Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias Unknown status NCT02303639 Phase 4 Antiarrhythmic drug therapy
8 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly Completed NCT00701675 Phase 4 sertraline 50 mg daily;sertraline 100 mg daily;Placebo 50 or 100 mg
9 Escitalopram in Patients With Generalized Anxiety Disorder Completed NCT00902564 Phase 4 Escitalopram
10 A Study of Duloxetine in Elderly Generalized Anxiety Disorder Completed NCT01118780 Phase 4 Duloxetine;Placebo
11 Cognitive-Behavioral Therapy and Escitalopram for Generalized Anxiety Disorder(GAD) Completed NCT00219349 Phase 4 escitalopram
12 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
13 Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder Completed NCT00624780 Phase 4 Pregabalin;Lorazepam;Pregabalin;Placebo
14 Safety and Efficacy of Eszopiclone in Patients With Generalized Anxiety Disorder Completed NCT00235508 Phase 4 Eszopiclone (Lunesta)
15 Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
16 Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD) Completed NCT01172652 Phase 4 Ziprasidone;Placebo
17 Drug Therapy for Generalized Anxiety Disorder Among the Elderly Completed NCT00105586 Phase 4 Escitalopram
18 Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial Completed NCT02219880 Phase 4
19 Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder Completed NCT00113295 Phase 4 Continued Paroxetine CR;Quetiapine;Placebo
20 Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial. Completed NCT02039193 Phase 4
21 A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder Completed NCT00539357 Phase 4
22 Chamomile Therapy for Generalized Anxiety Completed NCT00645983 Phase 4
23 Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR Completed NCT00183274 Phase 4 Venlafaxine XR;Placebo
24 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects Completed NCT01033851 Phase 4
25 A Study of Risperidone Monotherapy in Bipolar Anxiety Completed NCT00167479 Phase 4 risperidone (Risperdal)
26 Aripiprazole for the Treatment of Refractory Anxiety Completed NCT00438386 Phase 4 Aripiprazole
27 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
28 Lorazepam-Induced Toxicity in the Aged Completed NCT00044642 Phase 4 Lorazepam
29 A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients Completed NCT01201967 Phase 4
30 Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction Completed NCT00174850 Phase 4 Gaitril
31 Ambien CR vs. Placebo For Treatment Of Insomnia Associated With Anxiety When Used Concomitantly With Escitalopram (Lexapro) Completed NCT00296790 Phase 4 zolpidem tartrate
32 Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder Completed NCT00892463 Phase 4 Quetiapine (Seroquel) XR
33 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
34 Black Cohosh as Alternative Therapy for Treating Menopause-Related Anxiety Completed NCT00120458 Phase 4
35 A Double Blind, Randomized Placebo Controlled Study of the Efficacy, Safety and of Quetiapine Fumarate (Seroquel®) as Potentiation SSRI's, and SNRI's Treatment in Major Depression With Anxiety Completed NCT00229645 Phase 4 Quetiapine Fumarate (Seroquel®)
36 Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors Completed NCT00802919 Phase 4 Varenicline;Placebo for varenicline
37 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
38 Efficacy of Pethidine, Ketorolac And Xylocaine Gel As Analgesics For Pain Control In Shockwave Lithotripsy Completed NCT03032458 Phase 4 Pethidine;Ketorolac;Xylocaine Gel
39 Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial Completed NCT02263872 Phase 4 Minocycline
40 Genomics Used to Improve DEpression Decisions Completed NCT02109939 Phase 4
41 Duloxetine for Menopausal Depression Completed NCT01117857 Phase 4 Duloxetine
42 An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Completed NCT00385671 Phase 4 duloxetine hydrochloride;pregabalin;gabapentin
43 Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD Completed NCT03131050 Phase 4 Scopolamine;Escitalopram;Saline
44 Effectiveness of Integrating Prenatal Care in Reducing HIV/STDs Among Young Pregnant Women Completed NCT00628771 Phase 4
45 A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation Completed NCT02875366 Phase 4 LUM/IVA;Placebo
46 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
47 Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation Completed NCT01164592 Phase 4
48 Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities Recruiting NCT01975480 Phase 4 Desvenlafaxine
49 Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders Recruiting NCT03277339 Phase 4 Paroxetine
50 Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease Recruiting NCT02622022 Phase 4 Morphine hydrochloride

Search NIH Clinical Center for Generalized Anxiety Disorder

Genetic Tests for Generalized Anxiety Disorder

Anatomical Context for Generalized Anxiety Disorder

MalaCards organs/tissues related to Generalized Anxiety Disorder:

41
Brain, Heart, Testes, Amygdala, Cortex, Prefrontal Cortex, Breast

Publications for Generalized Anxiety Disorder

Articles related to Generalized Anxiety Disorder:

(show top 50) (show all 1104)
# Title Authors Year
1
Corrigendum to "Taxonicity and network structure of generalized anxiety disorder and major depressive disorder: An admixture analysis and complex network analysis." [Journal of Affective Disorders, 199 (2016) 99-105]. ( 30189353 )
2019
2
Mobile and traditional cognitive behavioral therapy programs for generalized anxiety disorder: A cost-effectiveness analysis. ( 29300754 )
2018
3
Efficacy of vortioxetine in working patients with generalized anxiety disorder- ERRATUM. ( 29880074 )
2018
4
Compromised dynamic cerebral autoregulation in patients with generalized anxiety disorder: a study using transfer function analysis. ( 29859053 )
2018
5
Impact of generalized anxiety disorder (GAD) on prehospital delay of acute myocardial infarction patients. Findings from the multicenter MEDEA study. ( 29383439 )
2018
6
Kava for Generalized Anxiety Disorder: A Review of Current Evidence. ( 29641222 )
2018
7
Risk Factors, Clinical Presentations, and Functional Impairments for Generalized Anxiety Disorder in Military Personnel and the General Population in Canada. ( 29304289 )
2018
8
Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review. ( 29806492 )
2018
9
A neural biomarker, the error-related negativity, predicts the first onset of generalized anxiety disorder in a large sample of adolescent females. ( 29665048 )
2018
10
Psychiatrists' treatment preferences for generalized anxiety disorder. ( 29266492 )
2018
11
The Diagnostic Value of Malondialdehyde, Superoxide Dismutase and Catalase Activity in Drug NaA^ve, First Episode, Non-Smoker Generalized Anxiety Disorder Patients. ( 29397670 )
2018
12
Working Memory and Motor Activity: A Comparison Across Attention-Deficit/Hyperactivity Disorder, Generalized Anxiety Disorder, and Healthy Control Groups. ( 29704970 )
2018
13
Kundalini Yoga for Generalized Anxiety Disorder: An Exploration of Treatment Efficacy and Possible Mechanisms. ( 29698081 )
2018
14
Intolerance of uncertainty in youth with obsessive-compulsive disorder and generalized anxiety disorder: A transdiagnostic construct with implications for phenomenology and treatment. ( 29426573 )
2018
15
Worry amplifies theory-of-mind reasoning for negatively valenced social stimuli in generalized anxiety disorder. ( 29254067 )
2018
16
Cognitive Behavioral Therapy, Mindfulness, and Hypnosis as Treatment Methods for Generalized Anxiety Disorder. ( 29771217 )
2018
17
How to customize a bona fide psychotherapy for generalized anxiety disorder? A two-arms, patient blinded, ABAB crossed-therapist randomized clinical implementation trial design [IMPLEMENT 2.0]. ( 29614982 )
2018
18
The effect of mindfulness meditation training on biological acute stress responses in generalized anxiety disorder. ( 28131433 )
2018
19
Generalized anxiety disorder and associated factors in adults in the Amazon, Brazil: A population-based study. ( 29747135 )
2018
20
Generalized Anxiety Disorder (GAD) and Comorbid Major Depression with GAD Are Characterized by Enhanced Nitro-oxidative Stress, Increased Lipid Peroxidation, and Lowered Lipid-Associated Antioxidant Defenses. ( 29736827 )
2018
21
Letter to the editor regarding "Generalized anxiety disorder in urban China: Prevalence, awareness, and disease Burden" [J. Affect. Disord. 234 (2018) 89-96]. ( 29945733 )
2018
22
Abnormal spontaneous brain activity in patients with generalized anxiety disorder revealed by resting-state functional MRI. ( 29406370 )
2018
23
A population-based examination of the co-occurrence and functional correlates of chronic pain and generalized anxiety disorder. ( 29703452 )
2018
24
Changing patterns in the prevalence of posttraumatic stress disorder, major depressive episode and generalized anxiety disorder over 24 months following a road traffic crash: Results from the UQ SuPPORT study. ( 29738952 )
2018
25
Client reflections on confirmation and disconfirmation of expectations in cognitive behavioral therapy for generalized anxiety disorder with and without motivational interviewing. ( 29357757 )
2018
26
The efficacy of group metacognitive therapy for children (MCT-c) with generalized anxiety disorder: An open trial. ( 29145078 )
2018
27
Efficacy and Safety of a Formulated Herbal Granula, Jiu Wei Zhen Xin, for Generalized Anxiety Disorder: A Meta-Analysis. ( 29707037 )
2018
28
Neural functional architecture and modulation during decision making under uncertainty in individuals with generalized anxiety disorder. ( 29931835 )
2018
29
An exploratory study of salivary cortisol changes during chamomile extract therapy of moderate to severe generalized anxiety disorder. ( 29080520 )
2018
30
Audio Recording for Independent Confirmation of Clinical Assessments in Generalized Anxiety Disorder. ( 29721364 )
2018
31
Repetitive transcranial magnetic stimulation of the right parietal cortex for comorbid generalized anxiety disorder and insomnia: A randomized, double-blind, sham-controlled pilot study. ( 29871798 )
2018
32
Difficulty concentrating in generalized anxiety disorder: An evaluation of incremental utility and relationship to worry. ( 29175616 )
2018
33
Somatosensory amplification, health anxiety, and alexithymia in generalized anxiety disorder. ( 30416291 )
2018
34
Comorbidity of Attention Deficit Hyperactivity Disorder and Generalized Anxiety Disorder in children and adolescents. ( 30551325 )
2018
35
The symptoms at the center: Examining the comorbidity of posttraumatic stress disorder, generalized anxiety disorder, and depression with network analysis. ( 30502492 )
2018
36
Interpretation training to target repetitive negative thinking in generalized anxiety disorder and depression. ( 30507227 )
2018
37
Protective Factors Associated With Fewer Generalized Anxiety Disorder Symptoms Among Women Exposed to Intimate Partner Violence. ( 30526241 )
2018
38
The roles of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in predicting treatment remission in a Chinese Han population with generalized anxiety disorder. ( 30529313 )
2018
39
An 8-Week, Randomized, Phase 2, Double-Blind, Sequential Parallel-Group Comparison Study of Two Dose Levels of the GABAA Positive Allosteric Modulator PF-06372865 Compared With Placebo as an Adjunctive Treatment in Outpatients With Inadequate Response to Standard of Care for Generalized Anxiety Disorder. ( 30531477 )
2018
40
Acute Exercise Effects among Young Adults with Analog Generalized Anxiety Disorder. ( 30531490 )
2018
41
Generalized Anxiety disorder but not depression is associated with insomnia: a population based study. ( 30455849 )
2018
42
Cognitive functions in young adults with generalized anxiety disorder. ( 30458333 )
2018
43
The Association of Adolescent Facebook Behaviours with Symptoms of Social Anxiety, Generalized Anxiety, and Depression. ( 30487941 )
2018
44
Cognitive Behavior Therapy and Metacognitive Therapy: Moderators of Treatment Outcomes for Children with Generalized Anxiety Disorder. ( 30406900 )
2018
45
Competing indirect effects in a comparative psychotherapy trial for generalized anxiety disorder. ( 30407039 )
2018
46
Six-month prevalence and correlates of Generalized Anxiety Disorder among primary care patients aged 70 years and over: Results from the ESA-services study. ( 30418683 )
2018
47
Treatment of Comorbid Adult Attention-deficit/Hyperactivity Disorder and Generalized Anxiety Disorder: 2 Case Reports. ( 30427813 )
2018
48
Common environmental factors may underpin the comorbidity between generalized anxiety disorder and mood disorders via activated nitro-oxidative pathways. ( 30430941 )
2018
49
Cognitive performance of youth with primary generalized anxiety disorder versus primary obsessive-compulsive disorder. ( 30375085 )
2018
50
The association between symptoms of generalized anxiety disorder and appointment adherence, overnight hospitalization, and emergency department/urgent care visits among adults living with HIV enrolled in care. ( 30387009 )
2018

Variations for Generalized Anxiety Disorder

Expression for Generalized Anxiety Disorder

Search GEO for disease gene expression data for Generalized Anxiety Disorder.

Pathways for Generalized Anxiety Disorder

Pathways related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
2
Show member pathways
11.99 BDNF DRD2 HTR1A
3
Show member pathways
11.74 BDNF DRD2 MAOA
4
Show member pathways
11.71 DRD2 HTR1A HTR2A
5 11.71 BDNF HTR1A HTR2A HTR3A MAOA SLC6A4
6 11.69 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1
7
Show member pathways
11.44 COMT SLC6A2 SLC6A4
8
Show member pathways
11.18 MAOA SLC6A2 SLC6A4
9
Show member pathways
10.91 COMT MAOA SLC6A4
10
Show member pathways
10.78 COMT MAOA TPH1
11
Show member pathways
10.63 COMT MAOA
12 10.58 COMT MAOA
13 10.55 HTR1A HTR2A HTR3A MAOA SLC6A4 TPH1

GO Terms for Generalized Anxiety Disorder

Cellular components related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 CRHR1 DRD2 HTR1A HTR2A HTR3A SLC6A2
2 dendrite GO:0030425 9.72 BDNF COMT DRD2 HTR1A HTR2A
3 neuron projection GO:0043005 9.65 HTR3A RGS2 SLC6A2 SLC6A4 TPH1
4 axon GO:0030424 9.55 BDNF COMT DRD2 HTR2A HTR3A
5 integral component of presynaptic membrane GO:0099056 9.26 DRD2 HTR2A HTR3A SLC6A4
6 integral component of postsynaptic membrane GO:0099055 8.92 DRD2 HTR2A HTR3A SLC6A4
7 integral component of membrane GO:0016021 10.1 COMT CRHR1 DRD2 HTR1A HTR2A HTR3A

Biological processes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.71 DRD2 HTR3A RGS2
2 chemical synaptic transmission GO:0007268 9.62 HTR1A HTR2A HTR3A SLC6A2
3 response to amphetamine GO:0001975 9.61 DRD2 RGS2
4 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.6 HTR1A HTR2A
5 activation of phospholipase C activity GO:0007202 9.59 BDNF HTR2A
6 negative regulation of insulin secretion GO:0046676 9.58 DRD2 PSMD9
7 response to axon injury GO:0048678 9.58 DRD2 TSPO
8 temperature homeostasis GO:0001659 9.57 DRD2 HTR2A
9 behavioral response to cocaine GO:0048148 9.56 DRD2 HTR2A
10 vasoconstriction GO:0042310 9.55 HTR1A SLC6A4
11 memory GO:0007613 9.54 BDNF HTR2A SLC6A4
12 dopamine metabolic process GO:0042417 9.52 COMT DRD2
13 catecholamine metabolic process GO:0006584 9.51 COMT MAOA
14 neurotransmitter catabolic process GO:0042135 9.49 COMT MAOA
15 behavior GO:0007610 9.48 HTR1A HTR2A
16 monoamine transport GO:0015844 9.46 SLC6A2 SLC6A4
17 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.43 DRD2 HTR2A
18 negative regulation of voltage-gated calcium channel activity GO:1901386 9.4 CRHR1 DRD2
19 response to pain GO:0048265 9.33 COMT SLC6A2 TSPO
20 dopamine catabolic process GO:0042420 9.26 COMT MAOA
21 serotonin receptor signaling pathway GO:0007210 9.13 HTR1A HTR2A HTR3A
22 response to drug GO:0042493 9.1 COMT DRD2 HTR2A SLC6A2 SLC6A4 TSPO

Molecular functions related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.37 HTR1A HTR2A
2 G protein-coupled serotonin receptor activity GO:0004993 9.32 HTR1A HTR2A
3 G-protein alpha-subunit binding GO:0001965 9.26 HTR2A RGS2
4 neurotransmitter:sodium symporter activity GO:0005328 9.16 SLC6A2 SLC6A4
5 monoamine transmembrane transporter activity GO:0008504 8.96 SLC6A2 SLC6A4
6 serotonin binding GO:0051378 8.92 HTR1A HTR2A HTR3A SLC6A4

Sources for Generalized Anxiety Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....